Pharmacokinetics of the soybean isoflavone daidzein in its aglycone and glucoside form: A randomized, double-blind, crossover study

Abstract

Background: There are conflicting results in the literature on the bioavailability of isoflavones in the aglycone and the glucoside forms. Objective: The objective was to investigate the pharmacokinetics of the soy isoflavone daidzein (DAI) on oral administration of both the aglycone and glucoside form in a human intervention study. In addition, the pharmacokinetics of the bacterial and oxidative metabolites of DAI was assessed. Design: Seven German men aged 22-30 y participated in a randomized, double-blind study in a crossover design. After ingestion of pure DAI or pure daidzein-7-O-β-D- glucoside (DG) (1 mg DAI aglycone equivalent/kg body weight), blood samples were drawn before isoflavone administration and 1, 2, 3, 4.5, 6, 8, 10, 12, 24, and 48 h after the dose. Urine was collected before and 0-6, 6-12, and 12-24 h after the intake of the isoflavones. The concentrations of DAI and its major bacterial and oxidative metabolites in plasma and urine were measured with isotope dilution capillary gas chromatography-mass spectrometry. Results: The systemic bioavailability (area under the curve; AUCinf), the maximal plasma concentration (Cmax), and the cumulative recovery of DAI in urine after administration of DG were 3-6 times greater than after the ingestion of DAI. Except for equol, which was formed by only one volunteer, all other quantified metabolites exhibited 2-12 times greater AUCinf, C max, and urinary recoveries after consumption of DG. Conclusion: Our results show that DG exhibits a greater bioavailability than its aglycone when ingested in an isolated form. © 2008 American Society for Nutrition.